Lurasidone
Treatment for Bipolar Disorder
Typical Dosage: 20-120mg daily
Effectiveness
86%
Safety Score
55%
Clinical Trials
31
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
20-120mg daily
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$900
Side Effect Mgmt:$200
Total Annual:$16,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$90,000/QALY
QALYs Gained
0.65
Outcome-Based Costs
Cost per Responder
$26,833.3
Cost per Remission
$40,250
Comparison vs Quetiapine
Cost Difference
+$14,100/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Lurasidone Outcomes
for Bipolar Disorder
Efficacy Outcomes
Overall Effectiveness
+86%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Akathisia
+15%
Nausea
+12%
Somnolence
+12%
Parkinsonism
+7%
Weight gain
+5%
Sources:
Active Clinical Trials
2 active trials recruiting for Lurasidone in Bipolar Disorder
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NCT03396068ACTIVE NOT RECRUITINGPHASE3
72 participants
INTERVENTIONAL
Birmingham, United States +3 more
Started: Dec 1, 2019
Effects of Lurasidone on Left Ventricle Systolic Functions
NCT06695676NOT YET RECRUITING
62 participants
OBSERVATIONAL
Aydin, Turkey (Türkiye)
Started: Nov 1, 2024
Completed Clinical Trials
16 completed trials for Lurasidone in Bipolar Disorder
Lurasidone and Cognition in Bipolar I Disorder
NCT02147379COMPLETEDPHASE3
53 participants
INTERVENTIONAL
Vancouver, Canada
Started: May 1, 2014
Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients
NCT02731612COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Boston, United States +8 more
Started: May 8, 2017
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
NCT01575561COMPLETEDPHASE3
377 participants
INTERVENTIONAL
Dothan, United States +70 more
Started: Jun 1, 2012
Lurasidone Extended Use Study
NCT01485640COMPLETEDPHASE3
162 participants
INTERVENTIONAL
Kelowna, Canada +45 more
Started: Jun 1, 2011
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
NCT03902613COMPLETEDPHASE4
1 participants
INTERVENTIONAL
New York, United States
Started: Feb 7, 2019
Biosignatures of Latuda for Bipolar Depression
NCT02239094COMPLETEDNA
20 participants
INTERVENTIONAL
New York, United States
Started: Jan 1, 2015
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
NCT00868699COMPLETEDPHASE3
505 participants
INTERVENTIONAL
Escondido, United States +54 more
Started: Apr 1, 2009
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
NCT00868959COMPLETEDPHASE3
817 participants
INTERVENTIONAL
Little Rock, United States +150 more
Started: Apr 1, 2009
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
NCT01358357COMPLETEDPHASE3
965 participants
INTERVENTIONAL
Dothan, United States +104 more
Started: Jun 1, 2011
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
NCT01284517COMPLETEDPHASE3
356 participants
INTERVENTIONAL
Costa Mesa, United States +74 more
Started: Nov 1, 2010
Lurasidone Pediatric Bipolar Study
NCT02046369COMPLETEDPHASE3
350 participants
INTERVENTIONAL
Dothan, United States +65 more
Started: Mar 1, 2014
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
NCT01731119COMPLETEDPHASE2
9 participants
INTERVENTIONAL
Chapel Hill, United States
Started: Dec 1, 2012
A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
NCT01986114COMPLETEDPHASE3
495 participants
INTERVENTIONAL
Tokyo, Japan +7 more
Started: Jan 29, 2014
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
NCT01986101COMPLETEDPHASE3
525 participants
INTERVENTIONAL
Tokyo, Japan +7 more
Started: Feb 19, 2014
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NCT03395392COMPLETEDPHASE2, PHASE3
74 participants
INTERVENTIONAL
Culver City, United States +13 more
Started: May 12, 2022
Lurasidone Pediatric Pharmacokinetics Study
NCT01620060COMPLETEDPHASE1
105 participants
INTERVENTIONAL
Little Rock, United States +9 more
Started: Jun 1, 2012
Showing 20 of 31 total trials